Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)
Public ClinicalTrials.gov record NCT03718494. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prevention of Alzheimer's Disease in Women: Risks and Benefits of Hormone Therapy -Continuation of: "The Kronos Early Estrogen Prevention Study (KEEPS)"
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to investigate how blood flow to the brain affects cognition in women who are postmenopausal, and how the use of hormone therapy early in menopause might change brain function. The testing in this study will add to the knowledge about brain aging in women. Researchers will determine if blood flow to the brain, brain structure, and cognition differences among women who took hormones in the past as part of Kronos Early Estrogen Prevention Study (KEEPS; NCT00154180), are currently taking hormones, or never took menopausal hormones.
Study identification
- NCT ID
- NCT03718494
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 299 participants
Conditions and interventions
Conditions
Interventions
- Brain Magnetic Resonance Imaging (MRI) Diagnostic Test
- F-18 Florbetapir Positron Emission Tomography (PET) Imaging Diagnostic Test
- F-18 AV-1451 Positron Emission Tomography (PET) Imaging Diagnostic Test
- Neuropsychological Testing Other
Diagnostic Test · Other
Eligibility (public fields only)
- Age range
- 49 Years to 72 Years
- Sex
- Female
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 21, 2019
- Primary completion
- Aug 31, 2022
- Completion
- Aug 31, 2022
- Last update posted
- Jul 16, 2023
2019 – 2022
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner Health | Phoenix | Arizona | 85032 | — |
| University of California San Francisco | San Francisco | California | 94158 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Columbia University | New York | New York | 10027 | — |
| University of Utah | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03718494, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2023 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03718494 live on ClinicalTrials.gov.